• John R Horn, Maria Marzella Mantione, and John F Johanson.
• Department of Pharmacy Services, University of Washington Medical Center, Seattle, WA 98195-7630, USA. jrhorn@u.washington.edu
• J Am Pharm Assoc (2003). 2012 May 1;52(3):372-80.

ObjectivesTo define constipation, assess the pharmacist's role in identifying and treating constipation, and review clinical evidence for the efficacy, safety, and tolerability of polyethylene glycol (PEG) 3350 (MiraLAX-Merck Consumer Care), an osmotic laxative now available over the counter (OTC), across a variety of patient populations routinely encountered in pharmacy settings.Data SourcesSystematic PubMed search of the primary literature for constipation treatment guidelines and clinical trial results for PEG 3350.Data SynthesisPharmacists have a unique role in assisting patients with identifying and managing constipation. Multiple controlled clinical trials have established the efficacy, safety, and tolerability of PEG 3350 at its recommended dose of 17 g once daily. On the basis of this evidence, various professional groups have recommended PEG 3350 for use in improving stool frequency and consistency in patients with constipation. PEG 3350 is approved for short-term use, including treatment of constipation caused by medications.ConclusionPharmacists can play an important role in managing constipation with OTC agents. Compared with other available OTC agents, PEG 3350 can be recommended to patients suffering from constipation on the basis of a large body of clinical evidence supporting its efficacy and safety, as well as the high patient acceptance shown for its palatability and once-daily dosing.

24 keywords...

hide…